Skip to main
SYRE
SYRE logo

SYRE Earnings Dates & Reports

SYRE Most Recent Earnings

Report DateAug 5, 2025
Period EndingQ2 2025
Est. EPS-$0.72
Actual EPS-$0.49
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

SYRE Earnings per Share (EPS) History

Signup for full access
Browse free

SYRE Latest Earnings

The value each SYRE share was expected to gain vs. the value each share gained.

SYRE reported its most recent earnings on Aug 5, 2025 for Q2 2025, posting earnings per share (EPS) of -$0.49. This exceeded analysts' expectations of -$0.72 by 31.94%, marking a Beat.

For comparison, Spyre Therapeutics Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on 11/06/2025, with analysts projecting an EPS of -$0.75.

SYRE Earnings History

Earnings
Est. EPSActual EPSSurprise
Q3 2025Nov 6, 2025
-$0.75Next earnings call Nov. 6, 2025
Q2 2025Aug 5, 2025
-$0.72-$0.49-31.94%

SYRE Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Spyre Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange
Aug 5, 2025

SYRE Earnings FAQs

SYRE last reported earnings on Aug 5, 2025 for Q2 2025, posting an EPS of -$0.49, which Beat the estimate of -$0.72 by 31.94%.

For Q2 2025, SYRE reported an EPS of -$0.49, exceeding analysts' estimate of -$0.72 by 31.94%.

For Q2 2025, SYRE Beat expectations with an actual EPS of -$0.49 vs. an estimated EPS of -$0.72.

Following the last earnings report on Aug 5, 2025, SYRE's stock price moved — from — to —.

The next SYRE earnings call is scheduled for Nov. 6, 2025, where executives will discuss financial results and outlook.

Spyre Therapeutics Inc (SYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.